Ta Robert, Yang David, Hirt Christian, Drago Thomas, Flavin Richard
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Diagnostics (Basel). 2022 Apr 27;12(5):1087. doi: 10.3390/diagnostics12051087.
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. It is a clinically and morphologically heterogeneous entity that has continued to resist complete subtyping. Molecular subtyping efforts emerged in earnest with the advent of gene expression profiling (GEP). This molecular subtyping approach has continued to evolve simultaneously with others including immunohistochemistry and more modern genomic approaches. Recently, the veritable explosion of genomic data availability and evolving computational methodologies have provided additional avenues, by which further understanding and subclassification of DBLCLs is possible. The goal of this review is to provide a historical overview of the major classification timepoints in the molecular subtyping of DLBCL, from gene expression profiling to present day understanding.
弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤。它是一种临床和形态学上异质性的实体，一直难以实现完全分型。随着基因表达谱分析（GEP）的出现，分子分型工作开始认真开展。这种分子分型方法与包括免疫组织化学和更现代的基因组方法在内的其他方法同时不断发展。最近，基因组数据可用性的真正爆炸式增长和不断发展的计算方法提供了更多途径，通过这些途径可以进一步理解和对DLBCL进行亚分类。本综述的目的是提供DLBCL分子分型中主要分类时间点的历史概述，从基因表达谱分析到当今的理解。
